Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.
Immunotherapy with unconjugated CD20 monoclonal antibodies has proven effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD20 immunotherapy depletes mature B cells but does not effectively deplete pre-B or immature B cells, some B cell subpopulations, antibody-producing cells, or their malignant counterparts. Because CD19 is expressed earlier during B cell development, a therapeutic strategy for the treatment of early lymphoblastic leukemias/lymphomas was developed by using CD19-specific monoclonal antibodies in a transgenic mouse expressing human CD19. Pre-B cells and their malignant counterparts were depleted as well as antibody- and autoantibody-producing cells. These results demonstrate clinical utility for the treatment of diverse B cell malignancies, autoimmune disease, and humoral transplant rejection.
Yazawa
Norihito
N
Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA.
Hamaguchi
Yasuhito
Y
Poe
Jonathan C
JC
Tedder
Thomas F
TF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000917:Antibody Formation / Q000502:physiology; D018941:Antigens, CD19 / Q000235:genetics / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007167:Immunotherapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D017452:Receptors, IgG / Q000378:metabolism
D000911:Antibodies, Monoclonal; D018941:Antigens, CD19; D001323:Autoantibodies; D007136:Immunoglobulins; D017452:Receptors, IgG